Perspectives in nanomedicine-based research towards cancer therapies

Current Nanoscience

Volumn 7, Issue 2, 2011, Pages 142-152

  Rane, Yogesh M ^a   Souto, Eliana B ^b,c  

^a Pharma Research   (India)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Anti neoplastic drugs; Cancer; Cancer diagnosis; Gene therapy; Nanomedicine; Nanotechnology; Public health

Indexed keywords

ANTI-NEOPLASTIC DRUGS; CANCER; CANCER DIAGNOSIS; NANOMEDICINES; PUBLIC HEALTH;

CELL CULTURE; CELL PROLIFERATION; DISEASES; DRUG THERAPY; GENETIC ENGINEERING; MEDICAL NANOTECHNOLOGY; ONCOLOGY; TUMORS;

GENE THERAPY;

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASPARAGINASE; ASPARAGINASE MACROGOL; CHITOSAN; CISPLATIN; DAUNORUBICIN; DENDRIMER; DENILEUKIN DIFTITOX; DOXORUBICIN; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; GENEXOL PM; GOLD NANOPARTICLE; HEPATITIS B SURFACE ANTIGEN; IBRITUMOMAB TIUXETAN; LE SN 38; LURTOTECAN; MITOPODOZIDE; NANOPLATIN; NK911; ONCO TCS; OSI 221; PACLITAXEL; PACLITAXEL POLIGLUMEX; PK1; PK2; POLITEF; POLYLYSINE; POLYMER; SGN 15; SINGLE WALLED NANOTUBE; STEROID; SUPERPARAMAGNETIC IRON OXIDE; TARIQUIDAR; THERMODOX; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VINCRISTINE; ZINOSTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AIR POLLUTION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; BIOSAFETY; BIOSEPARATION; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESEARCH; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL POPULATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIAGNOSTIC VALUE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR IMAGING; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; SENTINEL LYMPH NODE; T CELL LYMPHOMA; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

EID: 79951712963     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341311794653640     Document Type: Article

References (120)

1. Pierotti, M. A.; Lombardo, C.; Rosano, C. Nanotechnology: going small for a giant leap in cancer diagnostics and therapeutics. Tumori, 2008, 94(2), 191-6.
2. Mazzola, L.; Commercializing nanotechnology. Nat. Biotechnol., 2003, 21(10), 1137-43.
3. Paull, R.; Wolfe, J.; Hebert, P.; Sinkula, M. Investing in nanotechnology. Nat. Biotechnol., 2003, 21(10), 1144-7.
4. Gwinn, M. R.; Vallyathan, V. Nanoparticles: health effects-pros and cons. Environ. Health Perspect., 2006, 114(12), 1818-25.
5. Mulder, W. J.; Strijkers, G. J.; van Tilborg, G. A.; Cormode, D. P.; Fayad, Z. A.; Nicolay, K. Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc. Chem. Res., 2009, 42(7), 904-14.
6. Azzazy, H. M.; Mansour, M. M; In vitro diagnostic prospects of nanoparticles. Clin. Chim. Acta., 2009, 403(1-2), 1-8.
7. Azzazy, H. M.; Mansour, M. M.; Kazmierczak, S. C; From diagnostics to therapy: prospects of quantum dots. Clin. Biochem., 2007, 40(13-14), 917-27.
8. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Nanomedicine: current status and future prospects. FASEB J., 2005, 19(3), 311-30.
9. Allen T. N.; Cullis P. R. Drug delivery systems: entering the mainstream. Science, 2004, 303, 1818-21.
10. Kumar, M. N.; Mohapatra, S. S.; Kong, X.; Jena, P. K.; Bakowsky, U.; Lehr, C. M. Cationic poly(lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents. J. Nanosci. Nanotechnol., 2004, 4(8), 990-94.
11. Baker, J. R. Jr; Dendrimer-based nanoparticles for cancer therapy. Hematol. Am. Soc. Hematol. Educ. Program., 2009, 708-19.
12. Bai, S.; Thomas, C.; Rawat, A.; Ahsan, F; Recent progress in dendrimer- based nanocarriers. Crit. Rev. Ther. Drug. Carrier. Syst., 2006, 23(6), 437-95.
13. Basu, S.; Chaudhuri, P.; Sengupta, S. Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle, 2009, 8(21), 3480-7.
14. Peng, G.; Tisch, U.; Adams, O.; Hakim, M.; Shehada, N.; Broza, Y. Y.; Billan, S.; Abdah-Bortnyak, R.; Kuten, A.; Haick, H; Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat. Nanotechnol., 2009, 4(10), 669-73.
15. O'Neal, D. P.; Hirsch, L. R.; Halas, N. J.; Payne, J. D.; West, J. L; Photothermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer. Lett., 2004, 209(2), 171-76.
16. Perkel, J. M. The ups and downs of nanobiotech. Scientist, 2004, 18(16), 14-18.
17. 111In-Chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin. Cancer Res., 2005, 11(19 Suppl), 7087s-97s.
18. El-Sayed, I. H.; Huang, X.; El-Sayed, M. A. Selective laser photothermal. therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold. nanoparticles. Cancer Lett., 2006, 239(1), 129-35.
19. Andresen, T. L.; Davidsen, J.; Begtrup, M.; Mouritsen, O. G.; Jorgensen, K; Enzymatic release of antitumor ether lipids by specific phospholipase A2. activation of liposome-forming prodrugs. J. Med. Chem., 2004, 47(7), 1694-703.
20. Sarin, H; Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J. Transl. Med.,. 2009, 7, 77.
21. Patil, Y.; Sadhukha, T.; Ma, L.; Panyam, J. Nanoparticle-mediated. simultaneous and targeted delivery of paclitaxel and tariquidar overcomes. tumor drug resistance. J. Control. Release, 2009, 136(1), 21-9.
22. Chithrani, B. D.; Stewart, J.; Allen, C.; Jaffray, D. A. Intracellular uptake,. transport, and processing of nanostructures in cancer cells. Nanomedicine,. 2009, 5(2), 118-27.
23. Gopalan, B.; Ito, I.; Branch, C. D.; Stephens, C.; Roth, J. A.; Ramesh, R; Nanoparticle based systemic gene therapy for lung cancer: molecular. mechanisms and strategies to suppress nanoparticle-mediated inflammatory. response. Technol. Cancer Res. Treat., 2004, 3(6), 647-57.
24. Mansouri, S.; Cuie, Y.; Winnik, F.; Shi, Q.; Lavigne, P.; Benderdour, M.; Beaumont, E.; ernandes, J. C; Characterization of folate-chitosan-DNA. nanoparticles for gene therapy. Biomaterials, 2006, 27(9), 2060-5.
25. Li, Z.; Zhu, S.; Gan, K.; Zhang, Q.; Zeng, Z.; Zhou, Y.; Liu, H.; Xiong, W.; Li, X.; Li, G; Poly-L-lysine-modified silica nanoparticles: a potential oral. gene delivery system. J. Nanosci. Nanotechnol., 2005, 5(8), 1199-203.
26. Dufes, C.; Keith, W. N.; Bilsland, A.; Proutski, I.; Uchegbu, I. F.; Schatzlein, A. G; Synthetic anticancer gene medicine exploits intrinsic antitumor activity.of cationic vector to cure established tumors. Cancer Res., 2005, 65(18), 8079-84.
27. Kaul, G.; Amiji, M; Tumor-targeted gene delivery using poly(ethylene. glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm. Res., 2005, 22(6), 951-61.
28. Prabha, S. abhasetwar, V; Nanoparticle-mediated wild-type p53 gene. delivery results in sustained antiproliferative activity in breast cancer cells. Mol. Pharm., 2004, 1(3), 211-9.
29. Bharali, D. J.; Klejbor, I.; Stachowiak, E. K.; Dutta, P.; Roy, I.; Kaur, N.; Bergey, E. J.; Prasad, P. N.; Stachowiak, M. K; Organically modified silica. nanoparticles: a nonviral vector for in vivo gene delivery and expression in. the brain. Proc. Natl. Acad. Sci. USA, 2005, 102(32), 11539-44.
30. Zhang, Y.; Chen, J.; Pan, Y.; Zhao, J.; Ren, L.; Liao, M.; Hu, Z.; Kong, L.; ang, J; A novel PEGylation of chitosan nanoparticles for gene delivery. Biotechnol. Appl. Biochem., 2007, 46(Pt 4), 197-204.
31. Yang, S. J.; Chang, S. M.; Tsai, K. C.; Chen, W. S.; Lin, F. H.; Shieh, M. J; Effect of chitosan-alginate nanoparticles and ultrasound on the efficiency of.gene transfection of human cancer cells. J. Gene. Med., 2010, 12(2), 168-79.
32. Green, J. J.; Langer, R.; Anderson, D. G. A combinatorial polymer library.approach yields insight into nonviral gene delivery. Acc. Chem. Res., 2008, [Epub ahead of print].
33. Farjo, R.; Skaggs, J.; Quiambao, A. B.; Cooper, M. J.; Naash, M. I; Efficient.non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS. One., 2006, 1, e38.
34. [34] Schanen, B. C.; Karakoti, A. S.; Seal, S.; Drake, D. R., 3rd Warren, W. L.; Self, W. T. Exposure to titanium dioxide nanomaterials provokes.nflammation of an in vitro human immune construct. ACS Nano., 2009, (9), 2523-32.
35. Borges, O.; Silva, M.; de Sousa, A.; Borchard, G.; Junginger, H. E.; Cordeiro-da-Silva, A; Alginate coated chitosan nanoparticles are an effective. subcutaneous adjuvant for hepatitis B surface antigen. Int. Immunopharmacol., 2008, 8(13-14), 1773-80.
36. Chognot, D.; Zambaux, M. F.; Bonneaux, F.; Gaussem, P.; Pittet, J. L.; iach, M.; Vigneron, C; Identification of protein C epitopes altered during. its nanoencapsulation. J. Protein Chem., 1999, 18(7), 779-84.
37. Daniels, D. R. Theory of simple biochemical shape recognition via.diffusion from activator coated nanoshapes. J. Chem. Phys., 2008, 129(12),.125103.
38. Kaur, T.; Slavcev, R. A.; Wettig, S. D;Addressing the challenge: current and. future directions in ovarian cancer therapy. Curr. Gene. Ther., 2009, 9(6),.434-58.
39. Liu, Y.; Jiao, F.; Qiu, Y.; Li, W.; Qu, Y.; Tian, C.; Li, Y.; Bai, R.; Lao, F.; Zhao, Y.; Chai, Z.; Chen, C; Immunostimulatory properties and enhanced. TNF- alpha mediated cellular immunity for tumor therapy by C60(OH)20. nanoparticles. Nanotechnology, 2009, 20(41), 415102.
40. Lucarelli, R. T.; Ogawa, M.; Kosaka, N.; Turkbey, B.; Kobayashi, H.; Choyke, P. L.; New approaches to lymphatic imaging. Lymphat. Res. Biol., 2009, 7(4), 205-14.
41. Oliveira, M. D.; Correia, M. T.; Diniz, F. B. Concanavalin A and polyvinyl.butyral use as a potential dengue electrochemical biosensor. Biosens. Bioelectron., 2009, 25(4), 728-32.
42. Pan, X.; Chen, L.; Liu, S.; Yang, X.; Gao, J. X.; Lee, R. J; Antitumor activity.of G3139 lipid nanoparticles (LNPs). Mol. Pharm., 2009, 6(1), 211-20.
43. Zeng, G.; Chen, J.; Zhong, L.; Wang, R.; Jiang, L.; Cai, J.; Yan, L.; Huang, D.; Chen, C. Y.; Chen, Z. W. NSOM- and AFM-based nanotechnology. elucidates nano-structural and atomic-force features of a Y. pestis V. immunogen-containing particle vaccine capable of eliciting robust response roteomic, 2009, 9(6), 1538-47.
44. Nel, A; Atmosphere. Air pollution-related illness: effects of particles. Science, 2005, 308(5723), 804-6.
45. Delfino, R. J.; Sioutas, C.; Malik, S. Potential role of ultrafine particles in.associations between airborne particle mass and cardiovascular health. Environ. Health Perspect., 2005, 113(8), 934-46.
46. Dockery, D. W.; Luttmann-Gibson, H.; Rich, D. Q.; Link, M. S.; Mittleman,.M. A.; Gold, D. R.; Koutrakis, P.; Schwartz, J. D.; Verrier, R. L. Association.of air pollution with increased incidence of ventricular tachyarrhythmias.recorded by implanted cardioverter defibrillators. Environ. Health Perspect., 2005, 113(6), 670-4.
47. Peters, A.; Dockery, D. W.; Muller, J. E.; Mittleman, M. A. Increased. particulate air pollution and the triggering of myocardial infarction. Circulation, 2001, 103(23), 2810-5.
48. Peters, A.; Liu, E.; Verrier, R. L.; Schwartz, J.; Gold, D. R.; Mittleman, M.; Baliff, J.; Oh, J. A.; Allen, G.; Monahan, K.; Dockery, D. W; Air pollution. and incidence of cardiac arrhythmia. Epidemiology, 2000, 11(1), 11-7.
49. Pope, C. A., 3rd; Burnett, R. T.; Thurston, G. D.; Thun, M. J.; Calle, E. E.; Krewski, D.; Godleski, J. J; Cardiovascular mortality and long-term exposure. to particulate air pollution: epidemiological evidence of general. pathophysiological pathways of disease. Circulation, 2004, 109(1), 71-7.
50. Peters, A.; Doring, A.; Wichmann, H. E.; Koenig, W.;Increased plasma.viscosity during an air pollution episode: a link to mortality? Lancet, 1997,. 349(9065), 1582-7.
51. Nemmar, A.; Hoet, P. H.; Vanquickenborne, B.; Dinsdale, D.; Thomeer, M.; Hoylaerts, M. F.; Passage of inhaled particles into the blood circulation in. humans. Circulation, 2002, 105(4), 411-14.
52. Brown, J. S.; Zeman, K. L.; Bennett, W. D.; Ultrafine particle deposition and.clearance in the healthy and obstructed lung. Am. J. Respir. Crit. Care Med. 2002, 166(9), 1240-7.
53. Kreyling, W. G.; Semmler, M.; Erbe, F.; Mayer, P.; Takenaka, S.; Schulz, H.; Oberdorster, G.; Ziesenis, A.; Translocation of ultrafine insoluble iridium. particles from lung epithelium to extrapulmonary organs is size dependent. but very low. J. Toxicol. Environ. Health, A, 2002, 65(20), 1513-30.
54. Oberdorster, G.; Sharp, Z.; Atudorei, V.; Elder, A.; Gelein, R.; Lunts, A.; Kreyling, W.; Cox, C; Extrapulmonary translocation of ultrafine carbon. particles following whole-body inhalation exposure of rats. J. Toxicol. Environ. Health A, 2002, 65(20), 1531-43.
55. Pope, C. A. R.; Dockery, D. W.; Kanner, R. E.; Villegas, G. M.; Schwartz, J.; Oxygen saturation, pulse rate, and particulate air pollution: A daily time-. series panel study. Am. J. Respir. Crit. Care. Med. 1999, 159(2), 365-72.
56. Shy, C.; Craison, J.; Williams, R.; Zweindinger, R; Cardiovascular responses.of elderly persons to particulate air pollution [Abstract]. Epidemiology, 1998, 9, S77.
57. Gold, D. R.; Litonjua, A. A.; Schwartz, J.; Verrier, M.; Milstein, R.; Larson; A. Cardiovascular vulnerability to particulate pollution [Abstract]. Am. J. Respir. Crit. Care Med., 1998, 157, A261.
58. Gong, H., Jr.; Linn, W. S.; Clark, K. W.; Anderson, K. R.; Geller, M. D; Sioutas; C. Respiratory responses to exposures with fine particulates and. nitrogen dioxide in the elderly with and without COPD. Inhal. Toxicol, 2005, 17(3), 123-32.
59. Koenig, J. Q.; Mar, T. F.; Allen, R. W.; Jansen, K.; Lumley, T.; Sullivan, J. H.; Trenga, C. A.; Larson, T.; Liu, L. J.; Pulmonary effects of indoor- and. outdoor-generated particles in children with asthma. Environ. Health.Perspect., 2005, 113(4), 499-503.
60. Pietropaoli, A. P.; Frampton, M. W.; Hyde, R. W.; Morrow, P. E.; Oberdorster, G.; Cox, C.; Speers, D. M.; Frasier, L. M.; Chalupa, D. C.; Huang, L. S. Utell, M. J.; Pulmonary function, diffusing capacity, and. inflammation in healthy and asthmatic subjects exposed to ultrafine particles. Inhal. Toxicol., 2004, 16(Suppl 1), 59-72.
61. Silkoff, P. E.; Zhang, L.; Dutton, S.; Langmack, E. L.; Vedal, S.; Murphy, J. Make, B; Winter air pollution and disease parameters in advanced chronic. obstructive pulmonary disease panels residing in Denver, Colorado. J. Allergy Clin. Immunol., 2005, 115(2), 337-44.
62. Nemmar, A.; Hoet, P. H.; Vanquickenborne, B.; Dinsdale, D.; Thomeer, M.; Hoylaerts, M. F.; Vanbilloen, H.; Mortelmans, L.; Nemery, B.; Passage of.inhaled particles into the blood circulation in humans. Circulation, 2002,.105(4), 411-4.
63. Renwick, L. C.; Brown, D.; Clouter, A.; Donaldson, K.; Increased.inflammation and altered macrophage chemotactic responses caused by two. ultrafine particle types. Occup. Environ. Med., 2004, 61(5), 442-7.
64. Geiser, M.; Rothen-Rutishauser, B.; Kapp, N.; Schurch, S.; Kreyling, W.; Schulz, H.; Semmler, M.; Im Hof, V.; Heyder, J.; Gehr, P; Ultrafine particles. cross cellular membranes by nonphagocytic mechanisms in lungs and in. cultured cells. Environ. Health Perspect., 2005, 113(11), 1555-60.
65. Dick, C. A.; Brown, D. M.; Donaldson, K.; Stone, V.; The role of free.radicals in the toxic and inflammatory effects of four different ultrafine.particle types. Inhal. Toxicol., 2003, 15(1), 39-52.
66. Donaldson, K.; Tran, C. L; Inflammation caused by particles and fibers. Inhal. Toxicol., 2002, 14(1), 5-27.
67. Saldiva, P. H.; Clarke, R. W.; Coull, B. A.; Stearns, R. C.; Lawrence, J.; Murthy, G. G.; Diaz, E.; Koutrakis, P.; Suh, H.; Tsuda, A.; Godleski, J. J; Lung inflammation induced by concentrated ambient air particles is related.to particle composition. Am. J. Respir. Crit. Care Med., 2002, 165(12), 1610-7.
68. Stoeger, T.; Reinhard, C.; Takenaka, S.; Schroeppel, A.; Karg, E.; Ritter, B.; Heyder, J.; Schulz, H; Instillation of six different ultrafine carbon particles. indicates a surface area threshold dose for acute lung inflammation in mice. Environ. Health Perspect., 2006, 114(3), 328-33.
69. Brown, D. M.; Wilson, M. R.; MacNee, W.; Stone, V.; Donaldson, K; Size dependent proinflammatory effects of ultrafine polystyrene particles: a role. for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol. Appl. Pharmacol., 2001, 175(3), 191-9.
70. Oberdorster, G.; Gelein, R. M.; Ferin, J.; Weiss, B; Association of particulate.air pollution and acute mortality: involvement of ultrafine particles? Inhal. Toxicol., 1995, 7(1), 111-24.
71. Oberdorster, G; Pulmonary effects of inhaled ultrafine particles. Int. Arch. Occup. Environ. Health, 2001, 74(1), 1-8.
72. Nel, A.; Xia, T.; Madler, L.; Li, N; Toxic potential of materials at the.nanolevel. Science, 2006, 311(5761), 622-7.
73. Prahalad, A. K.; Soukup, J. M.; Inmon, J.; Willis, R.; Ghio, A. J.; Becker, S.; Gallagher, J. E; Ambient air particles: effects on cellular oxidant radical. generation in relation to particulate elemental chemistry. Toxicol. Appl. Pharmacol., 1999, 158(2), 81-91.
74. Antonini, J. M.; Roberts, J. R.; Jernigan, M. R.; Yang, H. M.; Ma, J. Y. Clarke, R. W; Residual oil fly ash increases the susceptibility to infection and. severely damages the lungs after pulmonary challenge with a bacterial. pathogen. Toxicol. Sci., 2002, 70(1), 110-9.
75. Oberdörster, G.; Ferin, J.; Lehnert, B. E.; Correlation between particle size, in.vivo particle persistence, and lung injury. Environ. Health Perspect., 1994,.102(suppl 5), 173-79.
76. Shvedova, A. A.; Kisin, E. R.; Mercer, R.; Murray, A. R.; Johnson, V. J.;.Potapovich, A. I.; Tyurina, Y. Y.; Gorelik, O.; Arepalli, S.; Schwegler-Berry, D.; Hubbs, A. F.; Antonini, J.; Evans, D. E.; Ku, B. K.; Ramsey, D.; Maynard, A.; Kagan, V. E.; Castranova, V.; Baron, P.; Unusual inflammatory.and fibrogenic pulmonary responses to single-walled carbon nanotubes in.mice. Am. J. Physiol. Lung Cell. Mol. Physiol., 2005, 289(5), L698-708.
77. Lam, C. W.; James, J. T.; McCluskey, R.; Hunter, R. L; Pulmonary toxicity.of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal. instillation. Toxicol. Sci., 2004, 77(1), 126-34.
78. Warheit, D. B.; Laurence, B. R.; Reed, K. L.; Roach, D. H.; Reynolds, G. A.; Webb, T. R; omparative pulmonary toxicity assessment of single-wall.carbon nanotubes in rats. Toxicol. Sci., 2004, 77(1), 117-25.
79. Nemmar, A.; Hoylaerts, M. F.; Hoet, P. H.; Dinsdale, D.; Smith, T.; Xu, H.; Vermylen, J.; Nemery, B; ltrafine particles affect experimental thrombosis.in an in vivo hamster model. Am. J. Respir. Crit. Care Med., 2002, 166(7),.998-1004.
80. Oberdorster, G.; Maynard, A.; Donaldson, K.; Castranova, V.; Fitzpatrick, J.; Ausman, K.; Carter, J.; Karn, B.; Kreyling, W.; Lai, D.; Olin, S.; Monteiro-Riviere, N.; Warheit, D.; Yang, H.principles for characterizing the potential.human health effects from exposure to nanomaterials: elements of a. screening strategy. Part Fibre Toxicol., 2005, 2, 8.
81. Hoet, P. H.; Bruske-Hohlfeld, I.; Salata, O. V; Nanoparticles - known and unknown health risks. J. Nanobiotechnol., 2004, 2(1), 12.
82. Oberdorster, G.; Oberdorster, E.; Oberdorster, J.; anotoxicology: an.emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect., 2005, 113(7), 823-39.
83. Oberdorster, G.; Sharp, Z.; Atudorei, V.; Elder, A.; Gelein, R.; Kreyling, W. Cox, C; ranslocation of inhaled ultrafine particles to the brain. Inhal.Toxicol., 2004, 16(6-7), 437-45.
84. Adachi, K.; Buseck, P. R;Hosted and free-floating metal-bearing.atmospheric nanoparticles in mexico city. Environ. Sci. Technol. 2010, 44(7),.2299-2304.
85. Asgharian, B.; Price, O. T.; Deposition of ultrafine (nano) particles in the.human lung. Inhal. Toxicol., 2007, 19(13), 1045-54.
86. Auffan, M.; Rose, J.; Wiesner, M. R.; Bottero, J. Y; Chemical stability of.metallic nanoparticles: a parameter controlling their potential cellular toxicity.in vitro. Environ. Pollut., 2009, 157(4), 1127-33.
87. Auger, F.; Gendron, M. C.; Chamot, C.; Marano, F.; Dazy, A. C.; Responses.of well-differentiated nasal epithelial cells exposed to particles: role of the.epithelium in airway inflammation. Toxicol. Appl. Pharmacol., 2006, 215(3),.285-94.
88. Aust, W.; Daum, N.; Bloching, M.; Armbruster, V.; Jung, E.; Sprau, C.; Muller, M.; Boehm, A.; Mozet, C.; Wichmann, G.; Dietz A.; Risk of. nanoparticles?. Laryngorhinootologie, 2009, 88(3), 162-6.
89. Boxall, A. B.; Tiede, K.; Chaudhry, Q. Engineered nanomaterials in soils and. water: how do they behave and could they pose a risk to human health?. Nanomedicine (Lond), 2007, 2(6), 919-27.
90. Madl, A. K.; Pinkerton, K. E.; Health effects of inhaled engineered and.incidental nanoparticles. Crit. Rev. Toxicol., 2009, 39(8), 629-58.
91. Feng, S. S; anoparticles of biodegradable polymers for new-concept.chemotherapy. Expert. Rev. Med. Dev., 2004, 1(1), 115-25.
92. Feng, Y.; Tinsley Oden, J.; Rylander, M. N.; two-state cell damage model.under hyperthermic conditions: theory and in vitro experiments. J. Biomech. Eng., 2008, 130(4), 041016.1-041016.10.
93. Lammers, T.; Hennink, W. E.; Storm, G. Tumour-targeted nanomedicines:. principles and practice. Br. J. Cancer, 2008, 99(3), 392-7.
94. Lammers, T.; Subr, V.; Peschke, P.; Kuhnlein, R.; Hennink, W. E.; Ulbrich, K.; Kiessling, F.; Heilmann, M.; Debus, J.; Huber, P. E.; Storm, G. Image-guided and passively tumour-targeted polymeric nanomedicines for.radiochemotherapy. Br. J. Cancer, 2008, 99(6), 900-10.
95. Leary, S. P.; Liu, C. Y.; Apuzzo, M. L.; Toward the emergence of nano-.neurosurgery: part III--nanomedicine: targeted nanotherapy, nanosurgery, and progress toward the realization of nanoneurosurgery. Neurosurgery,.2006, 58(6), 1009-26; discussion 1009-26.
96. Prokop, A.; Davidson, J. M; anovehicular intracellular delivery systems. J. Pharm. Sci., 2008, 97(9), 3518-90.
97. Ratnam, D. V.; Ankola, D. D.; Bhardwaj, V.; Sahana, D. K.; Kumar, M. N; Role of antioxidants in prophylaxis and therapy: A pharmaceutical. perspective. J. Control. Release, 2006, 113(3), 189-207.
98. Nune, S. K.; Chanda, N.; Shukla, R.; Katti, K.; Kulkarni, R. R.; Thilakavathi,.S.; Mekapothula, S.; Kannan, R.; Katti, K. V.; Green nanotechnology from.tea: phytochemicals in tea as building blocks for production of biocompatible.gold nanoparticles. J. Mater. Chem., 2009, 19 (19), 2912-2920.
99. Tseng, Y. C.; Huang, L. Self-assembled lipid nanomedicines for siRNA. tumor targeting. J. Biomed. Nanotechnol., 2009, 5(4), 351-63.
100. Thomas, D. G.; Pappu, R. V.; Baker, N. A. Ontologies for cancer. nanotechnology research. Conf. Proc. IEEE Eng. Med. Biol. Soc., 2009,. 2009, 4158-61.
101. Wang, S. L.; Yao, H. H.; Qin, Z. H; trategies for short hairpin RNA.delivery in cancer gene therapy. Expert Opin. Biol. Ther., 2009, 9(11), 1357-68.
102. Arias, J. L.; Reddy, L. H.; Couvreur, P; Polymeric nanoparticulate system. augmented the anticancer therapeutic efficacy of gemcitabine. J. Drug. Target, 2009, 17(8), 586-98.
103. Aryal, S.; Pilla, S.; Gong, S. Multifunctional nano-micelles formed by. amphiphilic gold-polycaprolactone-methoxy poly(ethylene glycol) (Au-PCL-. MPEG) nanoparticles for potential drug delivery applications. J. Nanosci. Nanotechnol., 2009, 9(10), 5701-8.
104. Bangham, A. D.; Standish, M. M.; Watkins, J. C; iffusion of univalent ions.across the lamellae of swollen phospholipids. J. Mol. Biol., 1965, 13(1), 238-252.
105. Gregoriadis, G; The carrier potential of liposomes in biology and medicine. New Engl. J. Med., 1976, 295, 704-710.
106. Ringsdorf, H; Structure and properties of pharmacologically active polymers.J. Pol. Sci. Polym. Symp., 1975, 51, 135-153.
107. Duncan, R; Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer, 2006, 6, 688-701.
108. Vasey, P. A.; Kaye, S. B.; Morrison, R.; Twelves, C.; Wilson, P.; Duncan, R.; Thomson, A. H.; Murray, L. S.; Hilditch, T. E.; Murray, T; Phase I. clinical and pharmacokinetic study of PK1 [lsqb]N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin[rsqb]: first member of a new class.of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res.,. 1999, 5, 83-94.
109. Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P Hawkins, M.; O'Shaughnessy, J; Phase III trial of nanoparticle albumin- bound paclitaxel compared with polyethylated castor oil-based paclitaxel in. women with breast cancer. J. Clin. Oncol., 2005, 23(31), 7794-7803.
110. De Smedt, S. C.; Demeester, J.; Hennink, W. E; Cationic polymer based gene delivery systems. Pharm. Res., 2001, 17, 113-126.
111. Schiffelers, R. M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P. Y.; Scaria, P. V.; Woodle, M. C; Cancer siRNA therapy by tumour selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res., 2004, 32(19), e14.
112. Nishiyama, N.; Kataoka, K; Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Therap., 2006, 112(3), 630-648.
113. Nakagawa, S; Efficacy and safety of poly (gamma-glutamic acid) based.nanoparticles (gamma-PGA NPs) as vaccine carrier. Yakugaku Zasshi, 2008, 128 (11), 1559-65.
114. Allen, T. M; Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2002, 2, 750-763.
115. Park, J. W.; Benz, C. C.; Martin, F. J; Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin. Oncol., 2004, 31-S13,.196-205.
116. Seymour, L. W.; Ferry, D. R.; Anderson, D. G.; Hesslewood, S.; Julyan, P. J.; Poyner, R.; Doran, J.; Young, A. M.; Burtles, S.; Kerr, D. J; Hepatic drug.targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol., 2002, 20 (6), 1668-1676.
117. Matsumura, Y.; Gotoh, M.; Muro, K.; Yamada, Y.; Shirao, K.; Shimada, Y.; Okuwa, M.; Matsumoto, S.; Miyata, Y.; Ohkura, H.; Chin, K.; Baba, S.; Yamao, T.; Kannami, A.; Takamatsu, Y.; Ito, K.; Takahashi, K; Phase I and.pharmacokinetic study of MCC-465, a doxorubicin (DXR). encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol., 2004, 15(3), 517-525.
118. Kirpotin, D. B. Drummond, D. C. Shao, Y. Shalaby, M. R. Hong, K. Nielsen, U. B. Marks, J. D. Benz, C. C. Park, J. W; Antibody targeting of.ong-circulating lipidic nanoparticles does not increase tumour localization but does increase internalization in animal models. Cancer Res., 2006, 66(13), 6732-6740.
119. Torchilin, V. P; Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 2005, 4, 145-160.
120. Gupta, B.; Levchenko, T. S.; Torchilin, V. P; Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev., 2005, 57(4), 637-651.